NASDAQ: CRDLCardiol Therapeutics Inc Stock
$0.71+0.01 (+1.43%)
Updated Feb 3, 2023
CRDL Price
$0.71
Fair Value Price
N/A
Market Cap
$45.00M
52 Week Low
$0.47
52 Week High
$2.08
P/E
-2.16x
P/B
1.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.48M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$17M
Beta
1.55
Next Earnings
Mar 21, 2023
Ex-Dividend
N/A
Next Dividend
N/A
CRDL Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses developing anti-fibrotic and anti-inflammatory therapies to treat cardiovascular disease. Its lead product is CardiolRx, which reduces cardiovascular and respiratory events in patients hospitalized with COVID-19. The company is also developing a subcutaneous formulation of CardiolRx to treat fibrosis and inflammation that progress to heart failure. Cardiol Therapeutics was incorporated in 2017 and is headquartered in Oakville, Ontario, Canada.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRDL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRDL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRDL is good value based on its book value relative to its share price (1.05x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.9x)
P/B vs Industry Valuation
CRDL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRDL due diligence checks available for Premium users.
Be the first to know about important CRDL news, forecast changes, insider trades & much more!
CRDL News
Valuation
CRDL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.16x
Industry
18.24x
Market
15.09x
CRDL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.05x
Industry
1.9x
CRDL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRDL's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
CRDL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$51.8M
Liabilities
$7.3M
Debt to equity
0.17
CRDL's short-term assets ($49.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRDL's short-term assets ($49.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRDL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
-$7.0k
Financing
-$10.5k
CRDL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRDL vs Pharmaceutical Stocks
Cardiol Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.